Find research datasets worth reusing

A Study of Modakafusp Alfa (TAK-573) Given by Itself and Together With Pembrolizumab in Adults With Advanced or Metastatic Solid Tumors

ClinicalTrials.gov study NCT04157517. IPD Sharing: YES. Countries: 2. Publications: 1.

restrictedIPD-UNDECIDEDFeb 2026View details →

A Phase III Study of BKM120 With Fulvestrant in Patients With HR+,HER2-, AI Treated, Locally Advanced or Metastatic Breast Cancer Who Progressed on or After mTORi

ClinicalTrials.gov study NCT01633060. IPD Sharing: UNDECIDED. Countries: 22. Publications: 1.

NIMBUS: Nivolumab Plus Ipilimumab in Metastatic Hypermutated HER2-negative Breast Cancer

ClinicalTrials.gov study NCT03789110. IPD Sharing: YES. Countries: 1. Publications: 1.

Study of Efficacy and Safety of Pembrolizumab Plus Platinum-based Doublet Chemotherapy With or Without Canakinumab in Previously Untreated Locally Advanced or Metastatic Non-squamous and Squamous NSCL

ClinicalTrials.gov study NCT03631199. IPD Sharing: YES. Countries: 41. Publications: 1.

restrictedIPD-UNDECIDEDFeb 2026View details →

Everolimus in Combination With Trastuzumab and Paclitaxel in the Treatment of HER2 Positive Locally Advanced or Metastatic Breast Cancer

ClinicalTrials.gov study NCT00876395. IPD Sharing: UNDECIDED. Countries: 28. Publications: 3.

A Study to Assess the Effectiveness and Safety of Irinotecan Liposome Injection, 5-fluorouracil/Leucovorin Plus Oxaliplatin in Patients Not Previously Treated for Metastatic Pancreatic Cancer, Compare

ClinicalTrials.gov study NCT04083235. IPD Sharing: YES. Countries: 18. Publications: 1.

Carboplatin-paclitaxel With Retifanlimab or Placebo in Participants With Locally Advanced or Metastatic Squamous Cell Anal Carcinoma (POD1UM-303/InterAACT 2).

ClinicalTrials.gov study NCT04472429. IPD Sharing: YES. Countries: 13. Publications: 2.

Efficacy and Safety of Vandetanib (ZD6474) in Patients With Metastatic Papillary or Follicular Thyroid Cancer

ClinicalTrials.gov study NCT00537095. IPD Sharing: YES. Countries: 7. Publications: 1.

Lapatinib +Capecitabine Treatment for Advanced Metastatic Breast Cancer in Women From China

ClinicalTrials.gov study NCT00508274. IPD Sharing: YES. Countries: 2. Publications: 1.

Telephone Support for Metastatic Breast Cancer Patients

ClinicalTrials.gov study NCT03998618. IPD Sharing: YES. Countries: 1. Publications: 1.

Pazopanib Versus Sunitinib in the Treatment of Asian Subjects With Locally Advanced and/or Metastatic Renal Cell Carcinoma

ClinicalTrials.gov study NCT01147822. IPD Sharing: YES. Countries: 3. Publications: 2.

publicOct 2024View details →

dryad40/100

Genomic, clinical data, and scripts for PD-1 blockade resistance in metastatic melanoma

Open the record for dataset details and reuse information.

opencc-by-4.0Nov 2024View details →

Deciphering genomic evolution of metastatic organotropism with 535 paired primary lung cancers and metastases

Scripts and processed data used in the analyses of the manuscript: Deciphering genomic evolution of metastatic organotropism with 535 paired primary lung cancers and metastases.

opencc-by-4.0Dec 2025View details →

Effect of Digoxin on clusters of circulating tumor cells in patients with metastatic breast cancer: a phase 1 trial

This repository contains processed transcriptomics data, large data sets and additional files required to reproduce the code available at the repository https://github.com/TheAcetoLab/dicct-trial

dryad36/100

Feasibility and metabolic outcomes of a well-formulated ketogenic diet as an adjuvant therapeutic intervention for women with stage IV metastatic breast cancer: The Keto-CARE trial

Purpose: Ketogenic diets may positively influence cancer through pleiotropic mechanisms, but only a few small and short-term studies have addressed feasibility and efficacy in cancer patients. The primary goals of this study were to evaluate the feasibility and the sustained metabolic effects of a personalized well-formulated ketogenic diet (WFKD) designed to achieve consistent blood beta-hydroxybutyrate (βHB) >0.5 mM in women diagnosed with stage IV metastatic breast cancer (MBC) undergoing chemotherapy. Methods: Women (n = 20) were enrolled in a six-month two-phase, single-arm WFKD intervention (NCT03535701). Phase I was a highly-supervised, ad libitum, personalized WFKD, where women were provided with ketogenic-appropriate food daily for three-months. Phase II transitioned women to a self-administered WFKD with ongoing coaching for an additional three-months. Fasting capillary βHB and glucose were collected daily; weight, body composition, plasma insulin, and insulin resistance were collected at baseline, three- and six-months. Results: Capillary βHB indicated women achieved nutritional ketosis (Phase I mean: 0.8 mM (n = 15); Phase II mean: 0.7 mM (n = 9)). Body weight decreased 10% after three-months, primarily from body fat. Fasting plasma glucose, plasma insulin, and insulin resistance also decreased significantly after three-months (p < 0.01), an effect that persisted at six-months. Conclusions: Women diagnosed with MBC undergoing chemotherapy can safely achieve and maintain nutritional ketosis, while improving body composition and insulin resistance, out to six-months.

opencc-zeroJan 2024View details →

dryad36/100

Data from: Pre- and post- treatment fold change plasma proteomics in metastatic NSCLC patients

Blood plasma samples were collected from advanced-stage NSCLC patients as part of a clinical study (PROPHETIC; NCT04056247). All clinical sites received IRB approval for the study protocol. Patient blood samples were drawn at baseline (referred to as T0) and, on average, 4 weeks after the treatment commenced, prior to the second dose of treatment (referred to as T1). Blood samples were drawn into tubes containing EDTA as an anticoagulant, and plasma was separated from the whole blood. The protocol adheres to the Clinical and Laboratory Standards Institute (CLSI) guidelines.

opencc-zeroFeb 2024View details →

opencc-by-4.0Mar 2022View details →

Raw Data for the article: Potential Anti-Metastatic Role of the Novel miR-CT3 in Tumor Angiogenesis and Osteosarcoma Invasion

Osteosarcoma (OS) is the most common primary bone tumor mainly occurring in young adults and derived from primitive bone-forming mesenchyme. OS develops in an intricate tumor microenvironment (TME) where cellular function regulated by microRNAs (miRNAs) may affect communication between OS cells and the surrounding TME. Therefore, miRNAs are considered potential therapeutic targets in cancer and one of the goals of research is to accurately define a specific signature of a miRNAs, which could reflect the phenotype of a particular tumor, such as OS. Through NGS approach, we previously found a specific molecular profile of miRNAs in OS and discovered 8 novel miRNAs. Among these, we deepen our knowledge on the fifth candidate renamed now miR-CT3. MiR-CT3 expression was low in OS cells when compared with human primary osteoblasts and healthy bone. Through TargetScan, VEGF-A was predicted as a potential biological target of miR-CT3 and luciferase assay confirmed it. We showed that enforced expression of miR-CT3 in two OS cell lines, SAOS-2 and MG-63, reduced expression of VEGF-A mRNA and protein, inhibiting tumor angiogenesis. Enforced expression of miR-CT3 also reduced OS cell migration and invasion as confirmed by soft agar colony formation assay. Interestingly, we found that miR-CT3 behaves inducing the activation of p38 MAP kinase pathway and modulating the epithelial-mesenchymal transition (EMT) proteins, in particular reducing Vimentin expression. Overall, our study highlights the novel role of miR-CT3 in regulating tumor angiogenesis and progression in OS cells, linking also to the modulation of EMT proteins.

opencc-by-4.0May 2024View details →

All datasets of primary tumors, primary or metastatic sites of metastatic tumors used in this study

All datasets of primary tumors, primary or metastatic sites of metastatic tumors used in this study

opencc-by-4.0Jun 2024View details →

KIR2DL2/DL3+NKs and Helios+Tregs in peripheral blood predict nivolumab response in patients with metastatic renal cell cancer

Purpose: To identify predictive factors of nivolumab sensitivity, peripheral blood NKs and Tregs were evaluated in patients with metastatic renal cancer (mRCC) enrolled in the REVOLUTION trial. Experimental design: 57 mRCCs being treated with nivolumab, as at least second-line of therapy (REV), and 62 healthy donors (HDs) were longitudinally evaluated (0-1-3-6-12 months) for peripheral NKs and Tregs, phenotype and function. Multivariable logistic regression were conducted to identify the independent predictors. The .632+ internal cross-validation was used to avoid overfitting. The best cut-off value based on three-months clinical-response was applied to progression-free survival (PFS) and overall survival (OS). Kaplan-Meier curves for PFS and OS were produced. Results: At pre-treatment, mRCCs displayed high frequency of NKp46+NKs, NKp30+NKs, KIR2DL1+NKs, KIR2DL2/DL3+NKs, and PD-1+NKs with reduced NK degranulation; as well as high frequency of Tregs, PD-1+Tregs, Helios+Tregs and ENTPD-1+Tregs. Responder patients (R), identified as a clinical response after three-months of treatment, presented at pre-treatment significantly low CD3+, high KIR2DL2/DL3+NKs, high PD-1+Tregs and high Helios+Tregs. Upon multivariate analysis, only KIR2DL2/DL3NKs and Helios+Tregs held as independent predictors of nivolumab responsiveness. The KIR2DL2/DL3+NKs >35.3% identified patients with longer OS while the Helios+Tregs >34.3% displayed significantly longer PFS. After 1-month of nivolumab, R patients showed low CD3+, high NKs, KIR2DL2/DL3+NKs and ICOS+Tregs. Among these subpopulations, CD3+ and KIR2DL2/DL3+NKs held as independent predictors of nivolumab efficacy. Low CD3+ (≤71%) significantly associated with longer PFS while high KIR2DL2/DL3+NKs (>23.3%) associated with both PFS and OS. Conclusions: Pre-treatment evaluation of Helios+Tregs/KIR2DL2/DL3+NKs and one-month post-treatment CD3+/ KIR2DL2/DL3+NKs will predict nivolumab response in mRCCs.